Hennie76 schreef op 2 juli 2015 10:28:
MW: MDxHealth SA (MDXH:EBR) a Belgian molecular diagnostics company, is adding to its platform of diagnostics by developing an advanced epigenetic test for personalized treatment of cancer. Its technology, MSP (methylation-specific PCR), is extremely powerful and accurate. It can detect a single cancer cell from among 10,000 healthy cells—including stem cells—in any type of bodily fluid or tissue.
"Immunotherapies targeting cancer, rare diseases and auto-immune diseases that are in Phase 2 or 3 with expected news flow in the next 3–6 months are the best candidates."
MDxHealth is partnering with Exact Sciences Corp. (EXAS:NASDAQ), which in-licensed all the technology for a specific test against colon cancer called Cologuard. This is the first FDA-approved, noninvasive test for colon cancer. On the market since late 2014, it showed very good revenues during the first quarter of 2015.
MDxHealth is getting about a 5% royalty on these sales. Analysts estimate Cologuard can generate up to $1.5B in revenue within the next few years. That would give MDxHealth a very good income stream.
Its current market value of about $200M is very much below the projected royalty income from this test alone. Some people suggest MDxHealth may be a takeover target for Exact Sciences.
TLSR: Why is MDxHealth so undervalued?
MW: MDxHealth is still seen as European company, even though the market for its diagnostic test is predominantly in the U.S. What the company should do, to increase its visibility to U.S. investors, is have a dual listing on a U.S. stock exchange, like NASDAQ, as several European companies have done.
Recently, the company successfully raised $31M, which it will use to increase its sales and clinical affairs efforts in the U.S. and to accelerate product development (new tests for prostate cancer and bladder cancer). This could be the step up for a NASDAQ listing in the near future.